en · de · es · pt
epitalon-notes.peptides3626.com › Topic › Structure, Naming And Discovery — Evidence Review

Structure, Naming And Discovery — Evidence Review

By Editorial Desk · published 2025-08-03 · last reviewed 2025-09-03 · Topic

epitalon comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-09-03. Where a claim depends on a specific study, the study is described rather than over-claimed.

Structure, Naming and Discovery

The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.

Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.

Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.

Peptide Identity and Laboratory Handling

Storage recommendations center on limiting moisture, heat, and light. The dry powder is generally kept at minus 20 degrees Celsius, and some suppliers recommend minus 80 degrees for long-term archival. Once dissolved, solutions are usually aliquoted and frozen to avoid repeated freeze-thaw cycles, which can promote aggregation or degradation. Aqueous stability depends on pH and concentration, and buffered saline is often preferred over plain water for biological work. Stability data specific to epitalon remain limited, so general peptide-handling practices are applied by analogy rather than from product-specific validation.

Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and its calculated monoisotopic mass is approximately 390.35 daltons. The compound does not occur naturally as a free peptide; it is produced by solid-phase peptide synthesis. Because it contains two acidic residues and no basic residues, the neutral form carries a net negative charge at physiological pH. This charge profile influences how the peptide behaves in solution and during chromatographic analysis.

Epitalon at a glance

PropertyValueNotes
Molecular formulaC14H22N4O9Derived from the four constituent residues
Molecular massAbout 390.35 DaMonoisotopic value, confirmed by mass spectrometry
Residue sequenceAla-Glu-Asp-GlyRead from the N-terminus to the C-terminus
Common synonymsEpithalon; AEDGBoth forms appear in reference catalogues
Net charge near neutral pHNegativeTwo acidic side chains give a low isoelectric point

Peptide Identity and Research Origin

Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.

The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.

Related pages on this site

Background from the literature

=== Specificity === The ATPase activity of TAP is highly dependent on the presence of the correct substrate, and peptide binding is prerequisite for ATP hydrolysis. This prevents waste of ATP via peptide-independent hydrolysis. The specificity of TAP proteins was first investigated by trapping peptides in the ER using glycosylation. TAP binds to 8- to 16-residue peptides with equal affinity, while translocation is most efficient for peptides that are 8 to 12 residues long. Efficiency reduces for peptides longer than 12 residues. However, peptides with more than 40 residues were translocated, albeit with low efficiency. Peptides with low affinity for the MHC class I molecule are transported out of the ER by an efficient ATP-dependent export protein. These outlined mechanisms may represent a mechanism for ensuring that only high-affinity peptides are bound to MHC class I.

== Therapeutic uses == Inhibition of the norepinephrine transporter (NET) has potential therapeutic applications in the treatment of attention deficit hyperactivity disorder (ADHD), substance abuse, neurodegenerative disorders (e.g., Alzheimer's disease (AD) and Parkinson's disease (PD)) and clinical depression.

The modifications covered in this diagram have to do with carbon skeleton modifications of the original fentanyl molecular structure. These are organized into methyl acetate additions, which are most known for the fentanyl -> carfentanil conversion. Many analogues of great potency, such as ohmfentanyl and lofentanyl possess methyl acetate groups added to the 4-carbon (of the piperidine ring, in the para- position relative to the annular nitrogen). The methyl acetate is added here from the α-carbon of the acetate moiety as it is with ohm- and lofentanyl. The 4-carbon is not a chiral center in carfetnanil because of a lack of piperidinyl substituents, but this same carbon is a chiral center in both ohm- and lofentanyl because both of those analogues have piperidinyl substituents. The second group are organized into methyl additions, which are known for the fentanyl analogues such as α-methylfentanyl and cis-3-methylfentanyl. These analogues can possess a wide variety of modified pharmacological properties, including increased and decreased potency (receptor binding efficiency), increased or decreased half-life (metabolic binding efficiency) or other side effects on human physiology. Other substituents such as hydroxy, chloro, fluoro, and a wide variety of alkyl groups, are also substituted in place of these methylations to produce psychoactive analogues of fentanyl, but because they often use the same skeletal naming conventions as the simple methyl analogues, we did not reproduce them all in the image here.

The nursing profession is already extremely short-staffed, strained and facing immense pressure – an unfortunate multi-year trend that was further exacerbated by the effects of the pandemic. This ruling will have a long-lasting negative impact on the profession." The American Bar Association issued a statement saying that, "A robust culture of safety relies on self-reporting and transparency to drive process improvement, and criminalizing errors instead foments blame and creates fear."

== Awards and honours == Uhlmann was elected a Fellow of the Royal Society (FRS) in 2015. His certificate of election reads: Frank Uhlmann's discovery with Nasmyth of 'separase', the protease that cleaves the cohesive links between sister chromatids to trigger anaphase is a key contribution to our understanding of the cell cycle. He has made major contributions to our understanding of the mechanisms of sister chromatid cohesion, and their relationship to cell cycle regulation. He generated the first chromosome-wide high resolution maps of proteins involved in chromosome packaging and segregation. He showed that yeast cohesins accumulate at sites of converging transcription distinct from the sites where their loading factors bind, apparently reflecting interaction with the transcription apparatus; and that cohesin loading factors are recruited to specific chromosomal sites through interaction with the nucleosome remodelling complex Rsc. He has identified genes required for cohesion establishment, and shown that one of these, EcoI, acetylates cohesin during DNA replication, thereby locking it onto DNA and his studies of the link between cohesion regulation and the cell cycle have shown that as well as cleaving cohesin, separase promotes mitotic exit by activating the Cdc14 phosphatase in a protease-independent manner. In 2006, Uhlmann was also elected a member of the European Molecular Biology Organization (EMBO) and awarded the EMBO Gold Medal.

Sources: en.wikipedia.org

Further detail

=== Famotidine === Famotidine is a specific, long-acting H2 antagonist that decreases gastric acid secretion. It is used in the treatment of peptic ulcer disease, GERD, and pathological hypersecretory conditions, like Zollinger–Ellison syndrome. (14,15) H2-receptor antagonists affect hormone metabolism, but their effect on glucose metabolism is not well established. (16) A study has revealed a glucose-lowering effect for famotidine. The study of famotidine binding to the enzyme has showed that famotidine can be docked within the binding pocket of GSK-3β making significant interactions with key points within the GSK-3β binding pocket. Strong hydrogen bond interactions with the key amino acids PRO-136 and VAL -135 and potential hydrophobic interaction with LEU-188 were similar to those found in the ligand binding to the enzyme (AR-A014418). Furthermore, famotidine showed high GSK-3β binding affinity and inhibitory activity due to interactions that stabilize the complex, namely hydrogen bonding of guanidine group in famotidine with the sulfahydryl moiety in CYS-199; and electrostatic interactions between the same guanidine group with the carboxyl group in ASP-200, the hydrogen bond between the terminal NH2 group, the OH of the TYR-143, and the hydrophobic interaction of the sulfur atom in the thioether with ILE-62. In vitro studies showed that famotidine inhibits GSK-3β activity and increases liver glycogen reserves in a dose dependent manner. A fourfold increase in the liver glycogen level with the use of the highest dose of famotidine (4.4 mg/kg) was observed.

== Expression == The FPR2 receptor is expressed on human neutrophils, eosinophils, monocytes, macrophages, T cells, synovial fibroblasts, and intestinal and airway epithelium. FPL2 is often co-expressed with FPR1. It is widely expressed by circulating blood neutrophils, eosinophils, basophils, and monocytes; lymphocyte T cells and B cells; tissue Mast cells, macrophages, fibroblasts, and immature dendritic cells; vascular endothelial cells; neural tissue glial cells, astrocytes, and neuroblastoma cells; liver hepatocytes; various types of epithelial cells; and various types of multicellular tissues.

== Causes == FOP is caused by an autosomal dominant allele on chromosome 2q23-24. The allele has variable expressivity, but complete penetrance. Most cases are caused by spontaneous mutation in the gametes; most people with FOP cannot or choose not to have children. A similar but less catastrophic disease is fibrous dysplasia, which is caused by a post-zygotic mutation. A mutation in the gene ACVR1 (also known as activin-like kinase 2 (ALK2)) is responsible for the disease. ACVR1 encodes activin receptor type-1, a BMP type-1 receptor. The mutation causes substitution of codon 206 from arginine to histidine in the ACVR1 protein. This substitution causes abnormal activation of ACVR1, leading to the transformation of connective tissue and muscle tissue into a secondary skeleton. This causes endothelial cells to transform to mesenchymal stem cells and then to bone. Normally, the ACVR1 gene encodes the activin receptor type-1 transmembrane kinase that bind BMP receptors (Type I BMPR and Type II BMPR) for chondrogenesis signaling. BMPs belong to a superfamily of proteins known as Transforming growth factor-beta (TGF-β) proteins. The binding of ACVR1 protein to BMP receptors start a signaling cascade that is crucial for inducing endochondral bone formation during development, as well as, skeletal and tissue homeostasis.

=== Toxicity === At present, the information needed to determine if HMX causes cancer is insufficient. Due to the lack of information, EPA has determined that HMX is not classifiable as to its human carcinogenicity. The available data on the effects on human health of exposure to HMX are limited. HMX causes CNS effects similar to those of RDX, but at considerably higher doses. In one study, volunteers submitted to patch testing, which produced skin irritation. Another study of a cohort of 93 workers at an ammunition plant found no hematological, hepatic, autoimmune, or renal diseases. However, the study did not quantify the levels of exposure to HMX. HMX exposure has been investigated in several studies on animals. Overall, the toxicity appears to be quite low. HMX is poorly absorbed by ingestion. When applied to the dermis, it induces mild skin irritation but not delayed contact sensitization. Various acute and subchronic neurobehavioral effects have been reported in rabbits and rodents, including ataxia, sedation, hyperkinesia, and convulsions. The chronic effects of HMX that have been documented through animal studies include decreased hemoglobin, increased serum alkaline phosphatase, and decreased albumin. Pathological changes were also observed in the animals' livers and kidneys. Gas exchange rate was used as an indicator of chemical stress in Northern bobwhite quail (Colinus virginianus) eggs, and no evidence of alterations in metabolic rates associated with HMX exposure was observed.

Sources: en.wikipedia.org

Frequently asked questions

What is epitalon made of?

It is a four-amino-acid peptide built from alanine, glutamate, aspartate and glycine in that order. Its formula is C14H22N4O9, and it is made by chemical synthesis rather than extracted from tissue. The synthetic peptide is a single defined molecule, unlike the pineal extracts it is often compared with.

Are epitalon and epithalon different compounds?

No. The two spellings refer to the same tetrapeptide, and the difference reflects transliteration from Russian. Laboratories and catalogues use both forms interchangeably. The material is also indexed as AEDG, taken from the one-letter codes of its residues.

How does epitalon differ from epithalamin?

Epithalamin is a mixed preparation derived from animal pineal tissue and contains many peptides. Epitalon is one synthetic sequence chosen for study from that broader mixture. Statements about one do not transfer directly to the other.

What is epitalon made of?

Epitalon is a synthetic tetrapeptide built from four amino acids: alanine, glutamate, aspartate, and glycine. It is not extracted from a natural source but made in the laboratory by chemical synthesis. Its short length makes it relatively straightforward to produce at high purity.

Network